FIGURE 6.

MAPK pathways involved in the anti-HBV activity of the peptide Mucroporin-M1 in vivo. The ERK and JNK MAP kinase pathways were activated in HBV-infected mice treated with an intravenous injection of Mucroporin-M1. Additionally, the expression of the HBV Core protein was also significantly reduced in mouse hepatocytes after intravenous injection of Mucroporin-M1. Group B, the mice treated by an intravenous injection of saline. Group M, the mice treated by an intravenous injection of Mucroporin-M1 peptide. Group P, the mice treated by both HBV plasmid and saline. Group T, the mice treated by both HBV plasmid and Mucroporin-M1 peptide.